Repurposing existing drugs for COVID-19: an endocrinology perspective
Correspondence
[키워드] absence
ACE inhibitor
ACE2
affected
Ageusia
aging
androgen
angiotensin receptor blocker
angiotensin-converting enzyme-2
Anosmia
Anti-androgen
ARB
arthralgia
assessment
candidate
caused
Clinical effect
clinical testing
clinical trial
coronavirus 2
correlated
COVID-19
COVID-19 patient
death
description
Dexamethasone
diabetes
drug
drug treatment
effective therapy
Efficacy
elicited
Endocrine
Evidence
familiarity
fatigue
Fever
Glucocorticoids
heterogeneous
Hospitalization
hypertension
include
Infection
inherent
inhibitor
lack
less
mechanical ventilation
methodological
Mild-to-moderate
myalgia
N-acetyl cysteine
NAC
obesity
Other
outcome
pandemic
patients
Perspective
public health systems
RAAS
reduce mortality
reduction in
repurposing
Research
researcher
respiratory
risk
Safe
safety profile
SARS-CoV-2
severe COVID-19
severely ill patient
Symptom
target
therapeutic options
TMPRSS2
transmembrane serine protease
while
with COVID-19
worse prognosis
[DOI] 10.1186/s12902-020-00626-0 PMC 바로가기 [Article Type] Correspondence
[DOI] 10.1186/s12902-020-00626-0 PMC 바로가기 [Article Type] Correspondence